Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by palinc2000on Nov 19, 2021 2:36pm
175 Views
Post# 34147282

RE:RE:RE:Hyping TH

RE:RE:RE:Hyping TH I think neither Paul nor Beliveau are happy about how the final edited version turned out.......The next time they will need to avoid such incompetent host who lacks knowledge of early stage clinical trials and who will never make it to the big league
I assume and hope that Paul nor Beliveau had seen the final version

While we are on this subject I dont think it adds to the investment thesis to presume that THTX is aware of some highly positive yet undisclosed results in Phase 1 which gives them a pass to act  in a certain way.....
ALL here are hoping for positive results ,,,,but nothing proven so far with regards to efficacy as we ALL know

SPCEO1 wrote: While I am not familiar with that person/show, I can still say that the best program for TH executives to be interviewed on, at least in regards to having a positive impact on the share price, would be CNBC or Fox Business channel. Or maybe something like 60 Minutes, but that is not likely.

jfm1330 wrote: The best program to really explain it fully would be Decouverte. I guess it will happen if they have great results on humans.


Mitchbeaude wrote:

I would have preferred an interview with Grald Fillion of Radio-Canada. It is a much more serious economic program with a facilitator who knows the economy well. Also Grald Filion knows the company Theratechnologie. He could have ask much more relevant questions.


 




<< Previous
Bullboard Posts
Next >>